SECOX as Neoadjuvant Therapy in Patients With Locally Advanced HCC (Q64795239)
Jump to navigation
Jump to search
clinical trial
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | SECOX as Neoadjuvant Therapy in Patients With Locally Advanced HCC |
clinical trial |
Statements
A Combination of Sorafenib, Capecitabine and Oxaliplatin (SECOX) as Neoadjuvant Therapy in Patients With Locally Advanced Hepatocellular Carcinoma: A Phase II Study (English)
0 references
20 June 2016
0 references
19 June 2021
0 references
45
0 references
18 year
0 references
75 year
0 references